What are the anticipated absolute effects of Angiotensin receptor antagonist (ARB) versus placebo (CKD class 3b-4) in Chronic Heart Failure?
The anticipated absolute effects of Angiotensin receptor antagonist (ARB) versus placebo (CKD class 3b-4) in Chronic Heart Failure are: All-cause mortality (from 32 fewer to 40 more); Combined outcome: cardiovascular mortality or HF admission (from 86 fewer to 25 more); Morbid event (includes hospitalisation and death) (from 82 fewer to 0 more); Renal function: change in eGFR (mean change in eGFR in the control groups was The mean in eGFR in the intervention groups was); Renal failure - progression to dialysis (Not estimable); Risk with Placebo (LOW due to risk of bias from 29 more to 104 more).